Skip to content
Kalpvruksh Markets
Offline Log in

JUBLPHARMANSEOffline

JUBILANT PHARMOVA · INE700A01033 · Small Cap · #430
947.05+7.50 (+0.80%)last close · 05 Nov 2026
Prev close
939.55
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹14,960 cr
52-week range · to 05 Nov 2026807.651,181.2

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

JUBLPHARMA is 20% below its 52-week high, above its 200-day average — a Small Cap company, #430 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 200-day averages · below its 50-day average · 20% below its 52-week high
  • +4.7% vs Nifty 500
  • traded value 0.4× usual · delivery 47% vs 49% usual
  • FPI −0.5 pp · DII +0.6 pp · MF schemes in Sept 2026: 8 bought, 39 cut · promoter pledge 6.6% · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹14,960 cr
Rank
#430
Cap band
Small Cap
Nearest cut-off — Mid / Small
−56.24% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.6×
median 72,731
Delivered
41,352
Of volume
51%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+0.1%−5.4 pts—
1 month−4.3%−8.5 pts—
3 months+2.4%+4.7 pts—
6 months−1.0%−1.4 pts—
1 year−15.3%−13.1 pts—

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+0.8%
above
vs 50-day average
−2.1%
below
vs 200-day average
+0.4%
above
ATR (14)
2.9%
typical daily range
Volatility
27%
1 month, annualised
Beta
0.71
vs Nifty 500, 1 year
Traded value
0.4×
vs usual
Delivery
47%
usual 49%
From the 52-week high
−19.8%
place in range 37% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters47.7%47.7%47.7%47.7%
FPI16.0%15.9% −0.115.9%15.4% −0.5
Mutual funds7.7%8.0% +0.39.0% +1.09.4% +0.4
Other DII3.5%3.6% +0.13.4% −0.23.6% +0.2
Individuals17.9%17.6% −0.317.2% −0.417.0% −0.1
Others7.3%7.2% −0.16.9% −0.36.9%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
6.6%
Of all shares
3.1%
Jun 25 noneSep 25 5.4%Dec 25 5.4%Mar 26 5.4%Jun 26 6.6%Sep 26 6.6%

Holders

Sep 26

All shareholders
82,602
Individuals
77,527

Indian passive funds’ stake

2026-06-30

Of free float
0.57%
Of all shares
0.30%
Schemes
43
Days to unwind
1.6
at 100% of volume

4,76,651 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
63
43 index · 20 active
Bought more
36
Sold some
9
FundSharesChangeDid
Tata India Pharma & Healthcare Fund-Reg(G)Active+85,248+167.5%bought
Bandhan Small Cap Fund-Reg(G)Active+12,22,392+48.2%bought
Bandhan Focused Fund-Reg(G)Active+90,000+8.6%bought
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)Active−53,799−46.0%sold
Kotak Special Opportunities Fund-Reg(G)Active−26,000−4.1%sold
HDFC NIFTY Smallcap 250 ETFIndex−787−0.8%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 262526831−2.3%₹612 cr
Aug 265453440+10.7%₹537 cr
Jul 2649027100+2.3%₹514 cr
Jun 2649128110+2.3%₹521 cr
May 2648220140+0.2%₹522 cr
Apr 264623031+2.3%₹486 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 5 of 19 disclosures
0 selected
12 Aug 2025SPB Trustee Company Private Limited and SS Trustee Company Private LimitedPromoter GroupPledge20,50,000₹221 cr20.08%Pledge Creation
12 Aug 2025HSB Trustee Company Private Limited and HS Trustee Company Private LimitedPromoter GroupPledge20,50,000₹221 cr19.00%Pledge Creation
13 Jun 2025Nikita Resources Private LimitedPromoter GroupSell19,62,434₹208 cr0.97%Others
13 Jun 2025Jubilant Enpro Private LimitedPromoter GroupSell21,16,000₹224 cr0.00%Others
13 Jun 2025SPB Trustee Company Private Limited and SS Trustee Company Private LimitedPromoter GroupSell7,00,000₹74.2 cr20.08%Others

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Credit rating
    Jubilant Pharmova Limited has informed the Exchange about Credit Rating
    22 Oct 2026
  • Credit rating
    Jubilant Pharmova Limited has informed the Exchange about Credit Rating
    15 Oct 2026
  • Board outcome
    Jubilant Pharmova Limited has informed the Exchange regarding Outcome of Board Meeting held on October 12, 2026 for the Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis
    12 Oct 2026
  • Board outcome
    Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    11 Aug 2026
  • Board outcome
    Outcome of Board Meeting-XBRL JUBILANT PHARMOVA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 22-May-2026 for Dividend
    25 May 2026
  • Board outcome
    Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    22 May 2026
  • Bulk deal: BUY
    11,00,000 at ₹915 — ABAKKUS FOUR2EIGHT OPPORTUNITIES FUND
    12 Oct 2026
  • Bulk deal: SELL
    11,00,000 at ₹915 — QUANT MUTUAL FUND
    12 Oct 2026
  • Block deal: BUY
    11,00,000 at ₹915 — ABAKKUS FOUR2EIGHT OPPORTUNITIES FUND
    12 Oct 2026
  • Block deal: SELL
    11,00,000 at ₹915 — QUANT MUTUAL FUND
    12 Oct 2026

Latest shown; 11 in six months on all disclosures.

JUBLPHARMA: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹5Final24 Jul 202624 Jul 2026
EarlierDividend₹5Final25 Jul 202525 Jul 2025
EarlierDividend₹5Final02 Aug 202402 Aug 2024
EarlierDividend₹5Final10 Aug 202310 Aug 2023
EarlierDividend₹5Final11 Aug 202212 Aug 2022
EarlierBonus3:5—12 Mar 200415 Mar 2004

6 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.